{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:09:44Z","timestamp":1788473384777,"version":"build-2803163510"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,30]],"date-time":"2023-01-30T00:00:00Z","timestamp":1675036800000},"content-version":"vor","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007857","name":"Stiftelsen Konung Gustaf V:s 80-\u00e5rsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005390","name":"Alfred \u00d6sterlunds Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005390","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011077","name":"Sk\u00e5nes universitetssjukhus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011077","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018740","name":"Anna-Greta Crafoords Stiftelse for Reumatologisk Forskning","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018740","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003252","name":"Lunds Universitet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006075","name":"Greta och Johan Kocks stiftelser","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.11.075","type":"journal-article","created":{"date-parts":[[2022,12,7]],"date-time":"2022-12-07T15:32:57Z","timestamp":1670427177000},"page":"504-510","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Reduced risk of serious pneumococcal infections up to 10\u00a0years after a dose of pneumococcal conjugate vaccine in established arthritis"],"prefix":"10.1016","volume":"41","author":[{"given":"J.","family":"Nagel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"J\u00f6nsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J-\u00c5.","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Manuswin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Englund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Saxne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Kapetanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.vaccine.2022.11.075_b0005","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1586\/erv.11.14","article-title":"Long-term protection after immunization with protein-polysaccharide conjugate vaccines in infancy","volume":"10","author":"Blanchard-Rohner","year":"2011","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.075_b0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rdc.2016.09.003","article-title":"Vaccines and disease-modifying antirheumatic drugs practical implications for the rheumatologist","volume":"43","author":"Friedman","year":"2017","journal-title":"Rheum Dis Clin N Am"},{"issue":"5","key":"10.1016\/j.vaccine.2022.11.075_b0015","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1128\/CVI.00721-15","article-title":"Pneumococcal vaccination in high-risk individuals: are we doing it right?","volume":"23","author":"Papadatou","year":"2016","journal-title":"Clin Vaccine Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.075_b0020","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","article-title":"2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"79","author":"Furer","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.11.075_b0025","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3899\/jrheum.170710","article-title":"A systematic review and metaanalysis of antirheumatic drugs and vaccine immunogenicity in rheumatoid arthritis","volume":"45","author":"Subesinghe","year":"2018","journal-title":"J Rheumatol"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2022.11.075_b0030","first-page":"2052","article-title":"The role of vaccination in preventing pneumococcal disease in adults","author":"Aliberti","year":"2014","journal-title":"Clin Microbiol Infect."},{"issue":"2","key":"10.1016\/j.vaccine.2022.11.075_b0035","doi-asserted-by":"crossref","first-page":"e001035","DOI":"10.1136\/rmdopen-2019-001035","article-title":"Efficacy, immunogenicity and safety of vaccination in adult patients with autoimmune inflammatory rheumatic diseases: a systematic literature review for the 2019 update of EULAR recommendations","volume":"5","author":"Rondaan","year":"2019","journal-title":"RMD Open."},{"issue":"35","key":"10.1016\/j.vaccine.2022.11.075_b0040","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.075_b0045","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.vaccine.2022.11.075_b0050","doi-asserted-by":"crossref","first-page":"270","DOI":"10.3181\/00379727-173-41643","article-title":"Long-term persistence of antibody following immunization with pneumococcal polysaccharide vaccine","volume":"173","author":"Mufson","year":"1983","journal-title":"Proc Soc Exp Biol Med"},{"issue":"5","key":"10.1016\/j.vaccine.2022.11.075_b0055","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/03009742.2020.1732459","article-title":"Pneumococcal antibody protection in patients with autoimmune inflammatory rheumatic diseases with varying vaccination status","volume":"49","author":"Rasmussen","year":"2020","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.vaccine.2022.11.075_b0060","doi-asserted-by":"crossref","first-page":"267","DOI":"10.3899\/jrheum.150397","article-title":"Longterm efficacy of an antipneumococcal polysaccharide vaccine among patients with autoimmune inflammatory rheumatic diseases","volume":"43","author":"Broyde","year":"2016","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.075_b0065","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1186\/ar4127","article-title":"Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs","volume":"15","author":"Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"41","key":"10.1016\/j.vaccine.2022.11.075_b0070","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.11.075_b0075","doi-asserted-by":"crossref","first-page":"950","DOI":"10.3346\/jkms.2016.31.6.950","article-title":"Impact of IgM antibodies on cross-protection against pneumococcal serogroups 6 and 19 after immunization with 7-Valent pneumococcal conjugate vaccine in children","volume":"31","author":"Cho","year":"2016","journal-title":"J Korean Med Sci"},{"issue":"10","key":"10.1016\/j.vaccine.2022.11.075_b0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2431-10-4","article-title":"Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?","volume":"2","author":"Hausdorff","year":"2010","journal-title":"BMC Pediatr"},{"issue":"13","key":"10.1016\/j.vaccine.2022.11.075_b0085","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1186\/1471-2334-13-474","article-title":"The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children","volume":"10","author":"Lee","year":"2013","journal-title":"BMC Infect Dis"},{"issue":"37","key":"10.1016\/j.vaccine.2022.11.075_b0090","doi-asserted-by":"crossref","first-page":"e4854","DOI":"10.1097\/MD.0000000000004854","article-title":"Serotype 6B from a pneumococcal polysaccharide vaccine induces cross-functional antibody responses in adults to serotypes 6A, 6C, and 6D","volume":"95","author":"Kim","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"10.1016\/j.vaccine.2022.11.075_b0095","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/acr.22246","article-title":"Effect of methotrexate, anti-tumor necrosis factor \u03b1, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"66","author":"Hua","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"4","key":"10.1016\/j.vaccine.2022.11.075_b0100","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/ard.2010.133371","article-title":"ARTIS study group. Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden","volume":"70","author":"Neovius","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.075_b0105","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/03009742.2010.493895","article-title":"ARTIS Study Group. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009","volume":"40","author":"Neovius","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"10.1016\/j.vaccine.2022.11.075_b0110","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1136\/ard.2010.137216","article-title":"EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases","volume":"70","author":"van Assen","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2022.11.075_b0115","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.vaccine.2015.01.065","article-title":"Low rate of influenza and pneumococcal vaccine coverage in rheumatoid arthritis: data from the international COMORA cohort","volume":"33","author":"Hmamouchi","year":"2015","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.11.075_b0120","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/03009742.2016.1242774","article-title":"Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA)","volume":"46","author":"Nguyen","year":"2017","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"10.1016\/j.vaccine.2022.11.075_b0125","doi-asserted-by":"crossref","first-page":"770","DOI":"10.3899\/jrheum.181376","article-title":"Suboptimal immunization coverage among Canadian rheumatology patients in routine clinical care","volume":"47","author":"Qendro","year":"2020","journal-title":"J Rheumatol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014992?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22014992?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:12Z","timestamp":1759404192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22014992"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X22014992"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.075","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced risk of serious pneumococcal infections up to 10\u00a0years after a dose of pneumococcal conjugate vaccine in established arthritis","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.075","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}